CSL ramps up development of COVID-19 plasma treatment

The Australian

6 May 2020 - Australia’s biggest health company CSL has confirmed it will immediately begin development of plasma-derived therapy to treat people suffering potentially lethal complications from coronavirus at its Broadmeadows’ factory.

The treatment involves extracting antibodies from the plasma of people who have recovered from COVID-19 and developing that into a hyperimmune immunoglobulin medicine to help coronavirus-infected patients, who have become seriously ill and in need of ventilation.

It is hoped the therapy will boost the immune system of COVID-19 patients, helping them combat the virus, which has killed more than 257,000 people and infected 3.7 million others worldwide.

Read The Australian article

Michael Wonder

Posted by:

Michael Wonder